Clinical Efficacy of Jinshuibao Capsules Combined with Angiotensin Receptor Blockers in Patients with Early Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials

Table 1

Overview for the general characteristics of the included studies.

Studies	Number		Age; (year)	Disease course (year)	Treatment (week)	Intervention		Outcome indicators
	EG/CG	M/F				EG	CG
Lv et al. 2006; [9]	48/32	44/36	EG: 49.5 ± 9.5; CG: 48.6 ± 8.9	/	16	JSB + Valsartan	Valsartan	UAER
Cao et al. 2007; [10]	30/30	28/32	EG: 59.4 ± 14.1; CG: 58.9 ± 11.2	EG: 8.4 ± 5.3; CG: 8.9 ± 5.0	24	JSB + Valsartan	Valsartan	UAER, ACR, SBP, DBP,
Lei et al. 2009; [11]	47/45	56/36	Total: 59.8 ± 7.1	Total: 8.3 ± 3.03	24	JSB + Irbesartan	Irbesartan	ORR, UAER, Scr, FBG, SBP, DBP,
Zhang 2010; [12]	40/40	42/38	EG: 54.2 ± 8.4; CG: 50.2 ± 10.5	EG: 0.3~10.3; CG: 0.2~10.8	8	JSB + Candesartan cilexetil	Candesartan cilexetil	ORR
Tang 2011; [13]	40/40	47/33	EG: 59.2 ± 3.8; CG: 57.7 ± 4.2	EG: 16 ± 3.6; CG: 17 ± 2.8	12	JSB + Telmisartan	Telmisartan	ORR, UAER, Scr, FBG, SBP, DBP,
Guo and Yan 2012; [14]	30/30	/	/	/	20	JSB + Irbesartan	Irbesartan	SBP, DBP
Li et al. 2012; [15]	38/38	42/34	EG: 48.6; CG: 49.3	EG: 7.4; CG: 7.7	8	JSB + Irbesartan	Irbesartan	ORR, 24 h UTP
Zhang et al. 2012; [16]	30/30	31/29	/	/	12	JSB + Valsartan	Valsartan	UAER, ACR, , TC, TG, SBP, DBP
Gao and Wei 2013; [17]	100/105	118/87	EG: 57.3 ± 5.7; CG: 59.3 ± 5.2	EG: 13.9 ± 4.5; CG: 14.5 ± 5.1	12	JSB + Valsartan	Valsartan	24 h UTP, BUN, Scr
Yang 2013; [18]	20/20	21/19	EG: 50.8 ± 7.39; CG: 49.1 ± 7.9	EG: 11.2 ± 5.3; CG: 10.7 ± 5.5	12	JSB + Losartan	Losartan	UAER, BUN, Scr, TC, TG, FBG,
Yu et al. 2013; [19]	40/40	52/28	Total: 47.6 ± 3.2	Total: 11.5 ± 2.9	12	JSB + Olmesartan Medoxomil	Olmesartan Medoxomil	24 h UTP, ACR
Ding 2014; [20]	50/50	52/48	Total: 51.2 ± 9.5	/	16	JSB + Irbesartan	Irbesartan	24 h UTP, BUN, Scr
Xiang 2014; [21]	60/60	71/49	EG: 41~71; CG: 42~70	/	12	JSB + Olmesartan Medoxomil	Olmesartan Medoxomil	ORR, UAER, Scr, ACR
Zhang et al. 2014; [22]	30/30	/	Total: 64 ± 6.3	/	8	JSB + Candesartan cilexetil	Candesartan cilexetil	UAER, BUN, SCr, SBP, TC, TG, Cys-C, β2-MG
Zhang and Zuo 2014 (2) [23]	41/41	69/13	Total: 50.4 ± 10.2	/	8	JSB + Losartan potassium	Losartan potassium	UAER, SCr, Cys-C
Shen et al. 2015; [24]	30/30	29/31	EG: 52.5 ± 6.9; CG: 51.5 ± 6.5	EG: 3.5 ± 2.8; CG: 3.4 ± 2.7	24	JSB + Candesartan	Candesartan	UAER, ACR, SBP, DBP,
Xu 2015; [25]	50/50	59/41	EG: 50.9 ± 5.1; CG: 52.1 ± 4.9	/	20	JSB + Irbesartan	Irbesartan	UAER, SBP, DBP
Zhu and Qiu 2015; [26]	30/30	31/29	EG: 40.9 ± 7.6; CG: 40.6 ± 7.5	/	20	JSB + Valsartan	Valsartan	24 h UTP, SBP, DBP
Dai 2016; [27]	45/45	64/26	EG: 52 ± 7.5; CG: 51 ± 7.5	EG: 10.3 ± 2.1; CG: 10.6 ± 1.5	28	JSB + Valsartan	Valsartan	24 h UTP, UAER, Scr, SBP, DBP,
Pan and Shang 2016; [28]	40/40	52/28	EG: 64.5 ± 4.7; CG: 65.7 ± 5.2	EG: 12.3 ± 5.9; CG: 11.6 ± 6.3	12	JSB + Telmisartan	Telmisartan	ACR, BUN, Scr, SBP, DBP, TC, TG, β2-MG
Wu and Pan 2016; [29]	34/34	40/28	EG: 52.12 ± 3.23; CG: 50.56 ± 4.12	Total: 7.84 ± 2.12	8	JSB + Candesartan cilexetil	Candesartan cilexetil	ORR, UAER, BUN, Scr, SBP, DBP, Cys-C, β2-MG
Xiu 2016; [30]	55/55	54/56	EG: 53.2 ± 6.8; CG: 52.8 ± 5.7	EG: 0.4~8.5; CG: 0.5~8.5	12	JSB + Candesartan	Candesartan	UAER, SBP, DBP,
Zhang 2016; [31]	33/34	33/34	EG: 56.4 ± 3.3; CG: 55.6 ± 4.1	EG: 5~10; CG: 6~9	12	JSB + Irbesartan	Irbesartan	UAER,
Cai 2017; [32]	50/50	51/49	EG: 65.2 ± 1.3; CG: 65.5 ± 1.2	/	12	JSB + Olmesartan Medoxomil	Olmesartan Medoxomil	24 h UTP, ACR
Liu and Zhang 2017; [33]	41/41	43/39	Total: 63.3 ± 5.7	/	8	JSB + Valsartan	Valsartan	ORR, BUN, Scr, SBP, DBP, FBG, , β2-MG
Zhu and Li 2017; [34]	53/53	62/44	EG: 52.9 ± 10.8; CG: 54.6 ± 10.4	EG: 8.9 ± 2.8; CG: 8.6 ± 2.5	8	JSB + Valsartan	Valsartan	UAER, Cys-C, β2-MG, SBP, DBP

EG, experimental group; CG, control group; M, male; F, female.